At Mirai Medical, we are passionate about developing technology that greatly improves cancer outcomes and enhances patient experiences.
Following intensive research and development, Mirai Medical was formed from a team with over 50 combined years of experience in the areas of pulsed electrical fields, electroporation for cancer, immunotherapy and medical device development to address critical unmet challenges in cancer treatment.
We have developed unique IP that allows for outpatient delivery of ePORE therapy which greatly facilitates the ease and improves the outcome of cancer treatment. The ePORE generator has associated probes for targeting tumours located anywhere on the body.
Omixon is a molecular diagnostics company that markets transplant diagnostic solutions to clinical and research laboratories.
Omixon uses its multidisciplinary competence ranging from bioinformatics, through software engineering to molecular diagnostics to design its products. Our goal is to enable histocompatibility labs to turn innovative technologies into better transplant outcomes.
A growing number of couples has trouble conceiving. Overall, 1 in 10 couples turn to IVF to solve the problem, but just 1 in 3 succeed after the first IVF cycle. Current methods for finding viable embryos, by examination under a microscope or by taking a biopsy for genetic testing, are slow and unreliable in predicting viability.
Annaida’s breakthrough technology will give doctors the ability to perform a fast, non-invasive and quantitative embryo screening, providing patients with an improved overall IVF success rate.
Lifespin GmbH, a deep data company developing a proprietary AI-based health testing platform to measure quantitative metabolic data in patient samples. Our platform is based on mapping metabolomics for human health and translating that data into health information that can be deployed in a wide range of pharmaceutical, research, and clinical settings. Lifespin’s health diagnostics software will be applicable in the broader healthcare space ranging from diagnostics to patient stratification and personalized medicine, as well as supporting the drug discovery process.
MedTrace Pharma A/S is working to eliminate diagnostic uncertainty by innovating medical imaging to help health care professionals diagnose patients better and faster. We are growing rapidly, backed by strong investors such as ATP, BankInvest, Swisscanto Private Equity, Vækstfonden and the European Innovation Council.
We create intelligent digital health solutions that facilitate decision making in clinical practice. Our goal is to improve lives of children and their families, avoid unnecessary hospital stays and reduce health care costs.
PreciHealth is a Swiss company that has developed the world’s first and only at home self-authenticating auto-injectors and blood collectors. The company was founded in 2017 as a medical spinoff of Preciflex, a leading enterprise that offers creative engineering solutions in the fields of micromechanics and microfluidics.
Unlike existing solutions, the PreciHealth platform enables governments and HMOs to perform en masse at-home vaccinations, injections and blood screenings, in which the patient's identity is authenticated, so there is no risk of patient mix-up or fraud. Furthermore, following each procedure, the patient receives a certification, and the procedure details can be seamlessly integrated into the HMO’s database.
The relevance of PreciHealth’s solution has never been more acute. With the growing Covid-19 pandemic and the need to vaccinate millions of people, PreciHealth offers an efficient and cost-effective solution that can play a major role in curbing the pandemic.
The PreciHealth platform is simple and easy to use. Once a patient receives the PreciHealth kit, s/he downloads a designated application that guides him/her throughout the procedure and verifies its completion.
The procedure itself is fast and painless. PreciHealth has developed patented micro-sized needles and lancets capable of penetrating the skin with unprecedented precision using very low force. The auto-injectors use an invisible needle which significantly reduces needle phobia. Furthermore, the needle penetrates the skin at an oblique angle which eliminates any needle injuries. The blood collection device uses a micro-lancet that creates a minute incision in the skin. The procedure takes only 10 minutes, yet delivers a high volume of capillary blood of between 150 μl to 2 ml of blood.
The PreciHealth management team consists of seasoned executives experienced in developing and marketing innovative medical devices.
Pristine Surgical is a medical technology company with a mission to simplify endoscopy.
We combine single-use endoscopes with cloud-based software to make visualization more efficient, consistent, and safe. And we offer a subscription business model with transparent pricing and automated inventory management for improved predictability and workflow.
Spindiag provides a rapid molecular point-of-care test. On our syndromic testing platform, we commercialized a SARS-CoV-2 test and are expanding the test menu towards a respiratory infections panel and detection of multi-drug resistant bacteria in 2022. Currently, Spindiag has an installed base of 150 systems in German hospitals and a cumulative turnover of > 5 M€ in 2021 so far. Spindiag's unique profile of a fast (40-50 minutes), very easy to use (just insert the patient swab sample) and broad (up to 36 parameters per patient sample tested) diagnostic solution makes it an attractive choice for hospitals and strategic investors.